

Passion for Innovation.
Compassion for Patients.™



Global Pharma Innovator with Competitive Advantage in Oncology

DAIICHI SANKYO CO., LTD.

Sunao Manabe
President and CEO

January 9, 2023

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward-looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

Agenda

1 Overview of Daiichi Sankyo

2 ENHERTU[®]

3 R&D Strategy

4 Shareholder Returns


5 Closing



Overview of FY2022 consolidated P&L

(Bn JPY)

	FY2022 Forecast	
		to revenue
Revenue	1250.0	100.0%
Cost of sales *1	338.0	27.0%
SG&A expenses *1	468.0	37.4%
R&D expenses *1	324.0	25.9%
Core operating profit *1	120.0	10.4%
Operating profit	130.0	10.4%
Profit attributable to owners of the Company	100.0	8.0%



*1 As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Income and expenses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses".


Temporary income and expenses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above.

*2 Asia, South & Central America

Our Proprietary Antibody Drug Conjugates (ADC)

T-DXd is an ADC composed of 3 components^{1,2}:

- A humanized anti-HER2 IgG1 mAb with the same amino acid sequence as trastuzumab, covalently linked to:
- A topoisomerase I inhibitor payload, an exatecan derivative, via
- A tetrapeptide-based cleavable linker



^aThe clinical relevance of these features is under investigation.

1. Nakada T, et al. *Chem Pharm Bull (Tokyo)*. 2019;67(3):173-185. 2. Ogitani Y, et al. *Clin Cancer Res*. 2016;22(20):5097-5108. 3. Trail PA, et al. *Pharmacol Ther*. 2018;181:126-142. 4. Ogitani Y, et al. *Cancer Sci*. 2016;107(7):1039-1046.

Payload mechanism of action:
topoisomerase I inhibitor^{a,1,2}

High potency of payload^{a,1,2}

High drug to antibody ratio ≈ 8 ^{a,1,2}

Payload with short systemic half-life^{a,1,2}

Stable linker-payload^{a,1,2}

Tumor-selective cleavable linker^{a,1,2}

Bystander antitumor effect^{a,1,4}

Goal and Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025)

Achieve FY2025 Goal “Global Pharma Innovator with Competitive Advantage in Oncology” and Shift to Further Growth

Maximize 3ADCs

- ◆ Maximize ENHERTU® and Dato-DXd through strategic alliance with AstraZeneca
- ◆ Maximize HER3-DXd without a partner
- ◆ Expand work force and supply capacity flexibly depending on changes around product potential

Profit growth for current business and products

- ◆ Maximize Lixiana® profit
- ◆ Grow Tarlige®, Nilemdo®, etc. quickly
- ◆ Transform to profit structure focused on patented drugs
- ◆ Profit growth for American Regent and Daiichi Sankyo Healthcare

Identify and build pillars for further growth

- ◆ Identify new growth drivers following 3ADCs
- ◆ Select and advance promising post DXd-ADC modalities

Create shared value with stakeholders

- ◆ Patients: Contributing to patients through “Patient Centric Mindset”
- ◆ Shareholders: Balanced investment for growth and shareholder returns
- ◆ Society: Environment load reduction across the value chain, and actions against pandemic risks
- ◆ Employees: Create one DS culture through fostering our core behaviors

- ◆ Data-driven management through DX, and company-wide transformation through advanced digital technology
- ◆ Agile decision making through new global management structure

Agenda

1 Overview of Daiichi Sankyo

2 **ENHERTU[®]**


3 R&D Strategy

4 Shareholder Returns

5 Closing



Steady increase in product sales due to market penetration and additional indications



Steady progress maximizing product value of ENHERTU® based on approval of new indications and strong market penetration

Transform the course of HER2+ BC

- Approved for **HER2+ BC 2L** in US based on DESTINY-Breast03 study which showed unparalleled improvement in PFS compared to T-DM1; started promotion in May 2022
- Established **leadership** in **HER2+ BC 2L** in US market
- **Expanding market to other countries and regions**

Pioneer HER2 low BC as a new clinically meaningful patient segment

- Approved for **HER2 low BC previously treated with chemotherapy** in US based on DESTINY-Breast04 study which showed potential to transform treatment for HER2 low patients; started promotion in August 2022
- **Rapid uptake** for HER2-low BC in US
- **Accelerating market expansion to other countries and regions**

Expand leadership across other HER2 targetable tumors

- Approved for **HER2 mutant NSCLC 2L+** in US based on DESTINY-Lung01 and 02 study; started promotion in August 2022
- **Approval for the third cancer type following BC and GC**
- **Accelerating market expansion to other countries and regions**

Provide new treatment option for previously “un-targetable” HER2 low BC patients; approximately half of all BC patients



Agenda

1 Overview of Daiichi Sankyo

2 ENHERTU[®]

3 **R&D Strategy**


4 Shareholder Returns

5 Closing




DS Strategy to Enrich Delivery to Patients


◆ 3 and Alpha strategy is evolving



Expand & Extend to Deliver Our Technology to More Patients




- Establish **DXd-ADC therapies** in Breast and Lung cancers
- Expand to **earlier and wider** patient segments with or without combinations
- Expand into **other cancer types** with high unmet medical needs



- Address unmet needs **after ENHERTU®** treatment
- Seek effective **treatment sequencing** between DXd-ADCs or novel assets including next-generation/new-concept ADCs
- Propose **novel combinations** to enhance efficacy


Establish and Expand DXd-ADCs to Address the Broader Spectrum of Breast Cancer



Launched
Ongoing study
Planning study
 Pivotal studies only, not exhaustive
 ET: endocrine therapy, HR: hormone receptor, TNBC: triple-negative breast cancer

* The numbers of treatment line in HR+ BC is chemotherapy lines after ET

Establish and Expand DXd-ADCs as New Treatment Options in Lung Cancer




Launched
Ongoing study
Planning study
Pivotal studies only, not exhaustive

Combinations to Expand DXd-ADC Opportunities

Combinations in ongoing study (examples, not exhaustive)

Ph1 or Ph2 Ph3



Agenda

1 Overview of Daiichi Sankyo

2 ENHERTU[®]

3 R&D Strategy

4 Shareholder Returns

5 Closing





Well-balanced Investment for Growth and Shareholder Returns

Cash Allocation

Prioritize R&D and capital investments for 3ADCs and pay dividends taking account of profit growth

Image for cash allocation



Prioritized investment for 3ADCs

Investment focused on enhancing ADC supply capabilities


Flexible allocation depending on pipeline progress for 1) investment to build pillars for further growth (in-house/external); and 2) acquisition of own shares

Stable dividends and dividend increase that take account of profit growth

Current cash in hands*
approx.
400.0 Bn JPY

*Cash in hands excluding working capital

Currency rate assumptions as of April 2021: 1 USD=105 JPY, 1 EUR=120 JPY



Increased annual dividend per share from 27 JPY to 30 JPY at FY2022 Q2 taking account of sales expansion of ENHERTU® more than expected

Agenda

1 Overview of Daiichi Sankyo

2 ENHERTU[®]

3 R&D Strategy

4 Shareholder Returns

5 Closing



FY2025 Financial Targets

◆ **Revenue**
1.6 Tr JPY

➤ **Oncology > 600.0 Bn JPY**

Achieve significant revenue/profit growth after investment for 3ADCs, and shift to a new stage for realizing 2030 vision

Revenue

960.0
Bn JPY

303.0
Bn JPY

Operating Profit* ratio
before R&D expense: 32%

FY2020 Estimate

FY2025 Target

FY2016-FY2020

5-Year Business Plan (FY2021-FY2025)

Investment for 3ADCs

Profit Growth

◆ **Core Operating Profit* ratio
before R&D expense: 40%**

◆ **ROE > 16%**

◆ **DOE > 8%**

*Excluding temporary income and expenses (gains and losses related to sale of fixed assets, restructuring, impairment, litigation, etc.)
FY2025 Currency rate assumptions as of April 2021: 1 USD=105 JPY, 1 EUR=120 JPY

5-Year Business Plan (FY2021-FY2025) for Sustainable Growth

We will achieve our 2025 Goal, **Global Pharma Innovator with Competitive Advantage in Oncology**, and will shift to further growth towards our 2030 Vision

2030 Vision

Innovative Global Healthcare Company Contributing to the Sustainable Development of Society

5-Year Business Plan (FY2021-FY2025)

Achieve FY2025 Goal "Global Pharma Innovator with Competitive Advantage in Oncology" and shift to further growth

As of FY2020

- ◆ Oncology business launched
- ◆ Edoxaban growing
- ◆ Regional value being enhanced
- ◆ AZ strategic alliance
- ◆ Increased RD investment

- ◆ Global top 10 in Oncology
- ◆ Additional growth pillars being source of revenue and profit
- ◆ New products being source of profit in each business unit
- ◆ Contributing to sustainable development of society through our business

Appendix



Regulatory decisions

Quizartinib

QuANTUM-First: AML, 1L, Ph3
• JP/US/EU: FY2023

Planned regulatory submissions

DS-5670

Ph1/2/3: COVID-19 mRNA vaccine, booster vaccination
• JP: FY2022 H2

Key data readouts

Dato-DXd

TROPION-Lung01*: NSCLC, 2/3L, Ph3
• FY2022 H2

HER3-DXd

HERTHENA-Lung01*: EGFR mutated NSCLC, 3L, Registrational Ph2
• FY2022 H2

Planned pivotal study initiation

Dato-DXd

TROPION-Lung07: non-squamous NSCLC w/o actionable genomic alterations, PD-L1 <50% 1L (pembrolizumab combo), Ph3
• FY2022 H2

Bold: update from FY2022 Q2

AML: acute myeloid leukemia, NSCLC: non-small cell lung cancer, TNBC: triple-negative breast cancer

Timeline indicated is based on the current forecast and subject to change.

*Event-driven study

** Adjuvant therapy for patients with TNBC with residual disease after neoadjuvant therapy

Major R&D Milestones (3ADCs)

Project	Target Indication [phase, study name]	FY2022		FY2023
		H1	H2	
ENHERTU®	• HER2+, 2L [P3, DESTINY-Breast03]	• Approved (US/EU)	• Approved (JP)	
	• HER2 low, post chemo [P3, DESTINY-Breast04]	• Filing accepted (JP/EU/China) • Approved (US)		• Approval anticipated (JP/EU)
	• HER2 low, chemo naïve [P3, DESTINY-Breast06]			• TLR anticipated
	• HER2+, 2L [P2, DESTINY-Gastric02, EU]		• Approved (EU)	
	• HER2 mutant, 2L [P2, DESTINY-Lung01, 02]	• Approved (US)	• Filing accepted (JP) • Filing anticipated (EU)	
	• HER2+, 3L [P2, DESTINY-CRC02]		• TLR anticipated	
Dato-DXd	• 2/3L [P3, TROPION-Lung01]		• TLR anticipated	
	• 1L [P3, TROPION-Lung07]		• Study start planned	
	• TNBC, adjuvant* [P3, TROPION-Breast03]		• Study started	
HER3-DXd	• EGFR mutated, 3L [Registrational P2, HERTHENA-Lung01]		• TLR anticipated	

Bold: update from FY2022 Q2 BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TLR: Top Line Results, TNBC: triple-negative breast cancer

Timeline indicated is based on the current forecast and subject to change.

* Adjuvant therapy for patients with TNBC who have residual disease after neoadjuvant therapy

Major R&D Milestones (Alpha)

Project	Target Indication [phase, study name]	FY2022		FY2023
		H1	H2	
Quizartinib	<ul style="list-style-type: none"> AML, 1L [P3, JP/US/EU] 	<ul style="list-style-type: none"> Filing accepted (JP/EU) 	<ul style="list-style-type: none"> Filing accepted (US) 	<ul style="list-style-type: none"> Approval anticipated (JP/US/EU)
DS-1211	<ul style="list-style-type: none"> PXE [P2, US/EU] 		<ul style="list-style-type: none"> Study started 	
DS-5670	<ul style="list-style-type: none"> COVID-19 mRNA vaccine, booster vaccination [P1/2/3, JP] 		<ul style="list-style-type: none"> TLR obtained Filing anticipated (JP) 	

Major R&D Pipeline: 3ADCs

Phase 1		Phase 2		Phase 3	Filed
(US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07	(JP/US) NSCLC, TNBC, HR+ BC, SCLC, GC, urothelial, esophageal, prostate, etc. TROPION-PanTumor01	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) endometrial, ovarian, prostate cancer, GC, CRC combo TROPION-PanTumor03	(JP/US/EU/Asia) HER2+ BC 3L DESTINY-Breast02	(China) HER2+ BC 2L DESTINY-Breast03
(US/EU/Asia) HER2 low BC Chemo naïve/ post chemo DESTINY-Breast08	(CN) NSCLC, TNBC TROPION-PanTumor02	(CN) HER2+ GC 3L DESTINY-Gastric06	(JP/US/EU/Asia) NSCLC (w/ actionable mutation) TROPION-Lung05	(JP/US/EU/Asia) HER2+ BC adjuvant* DESTINY-Breast05	(JP/EU/China) HER2 low BC post chemo DESTINY-Breast04
(JP/US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03	(JP/US/EU/Asia) NSCLC (pembrolizumab combo) TROPION-Lung02	(JP/US/EU) HER2+ or HER2 mutant NSCLC 2L~ DESTINY-Lung01	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06	(JP) HER2 mutant NSCLC 2L~ DESTINY-Lung01/Lung02
(EU/Asia) HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(JP/US/EU) NSCLC (durvalumab combo) TROPION-Lung04	(JP/US/EU/Asia) HER2 mutant NSCLC 2L~ DESTINY-Lung02	(JP/US/EU/Asia) EGFR mutated NSCLC 2L (osimertinib combo) ORCHARD	(JP/US/EU/Asia) HER2+ BC 1L DESTINY-Breast09	
(US/EU) BC, bladder (nivolumab combo)	(JP/US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(CN) HER2 mutant NSCLC 2L~ DESTINY-Lung05	(JP/US/EU/Asia) EGFR mutated NSCLC 3L HERTHENA-Lung01	(JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11	
(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU/Asia) NSCLC	(US/EU/Asia) NSCLC (durvalumab combo) 2L~ HUDSON		(JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04	
(US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(JP/US) EGFR mutated NSCLC (osimertinib combo)	(JP/US/EU) HER2+ CRC 3L DESTINY-CRC01		(JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L DESTINY-Lung04	
	(JP/US) HER3+ BC	(JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02		(JP/US/EU/Asia) NSCLC 2/3L TROPION-Lung01	
		(JP/US/EU/Asia) HER2 mutant tumor DESTINY-PanTumor02		(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembro combo) 1L TROPION-Lung07 (in prep.)	
		(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02		(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembro combo) 1L TROPION-Lung08	
				(JP/US/EU/Asia) HR+ BC 2/3L TROPION-Breast01	
				(JP/US/EU/Asia) TNBC 1L TROPION-Breast02	
				(JP/US/EU/Asia) TNBC adjuvant** TROPION-Breast03	
				(JP/US/EU/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02	

ENHERTU®

Dato-DXd

HER3-DXd

Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials






Breakthrough Designation (US) Orphan drug designation (JP)

* Adjuvant therapy for patients with HER2 positive early breast cancer with high risk of disease recurrence who have residual invasive disease after receiving neo-adjuvant therapy

** Adjuvant therapy for patients with TNBC who have residual disease after neoadjuvant therapy

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer


Major R&D Pipeline: Alpha

Phase 1		Phase 2		Phase 3		Filed	
<ul style="list-style-type: none"> DS-7300 (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, SCLC, etc. 	<ul style="list-style-type: none"> DS-6016 (JP) Anti-ALK2 antibody FOP 	<ul style="list-style-type: none"> Valemetostat (DS-3201)(JP/US/EU/Asia)   EZH1/2 inhibitor PTCL 	<ul style="list-style-type: none"> Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor 	<ul style="list-style-type: none"> Quizartinib (JP/US/EU)  FLT3 inhibitor AML 1L 			
<ul style="list-style-type: none"> DS-6000 (JP/US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer 	<ul style="list-style-type: none"> DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus 	<ul style="list-style-type: none"> Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL 	<ul style="list-style-type: none"> Esaxerenone (JP) MR blocker Diabetic nephropathy 	<ul style="list-style-type: none"> VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray 			
<ul style="list-style-type: none"> DS-1055 (JP/US) Anti-GARP antibody Solid tumors 	<ul style="list-style-type: none"> DS-2325 (US) KLK5 inhibitor Netherton syndrome 	<ul style="list-style-type: none"> DS-1001 (JP) Mutant IDH1 inhibitor Glioma 	<ul style="list-style-type: none"> VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine 				
<ul style="list-style-type: none"> DS-1594 (US) Menin-MLL binding inhibitor AML, ALL 		<ul style="list-style-type: none"> DS-7300 (JP/US/EU/Asia) B7-H3-directed ADC ES-SCLC 	<ul style="list-style-type: none"> DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (booster vaccination) 				
<ul style="list-style-type: none"> DS-9606 (US/EU) Target undisclosed ADC Solid tumors 		<ul style="list-style-type: none"> DS-5141 (JP) ENA oligonucleotide DMD  	<ul style="list-style-type: none"> DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (primary vaccination, adults) 				
		<ul style="list-style-type: none"> DS-1211 (US/EU) TNAP inhibitor Pseudoxanthoma elasticum  	<ul style="list-style-type: none"> DS-5670 (JP) COVID-19 mRNA vaccine, COVID-19 (primary vaccination, 5 to 11 aged children) 	<ul style="list-style-type: none"> DS-5670 (JP) COVID-19 mRNA vaccine, COVID-19 (primary vaccination, 12 to 17 aged children) (in prep.) 			
		<ul style="list-style-type: none"> VN-0200 (JP) RS virus vaccine RS virus infection 					

Oncology

Specialty medicine

Vaccine

 Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials

 SAKIGAKE Designation (JP)

 Orphan drug designation (JP/US/EU)

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma

ENHERTU®: Clinical Development Plan | Breast cancer

As of Dec 2022		FY2022	FY2023	FY2024
HER2 Positive	Metastatic 3L+	DESTINY-Breast02 monotherapy vs PC		
	Metastatic 2L	DESTINY-Breast03		
	Metastatic 1L	DESTINY-Breast07 combination (2L/1L) Ph1b/2		
	Adjuvant	DESTINY-Breast09 T-DXd ± pertuzumab vs THP		
	Neoadjuvant	DESTINY-Breast05 monotherapy vs T-DM1		
			DESTINY-Breast11 T-DXd vs T-DXd / THP vs AC / THP	
HER2-low	HR+ HR-	Metastatic Post Chemo	DESTINY-Breast04 mono vs PC	
		Adjuvant	DESTINY-Breast08 combination	
	HR+	Metastatic Chemo Naïve	DESTINY-Breast06 monotherapy vs PC	
	HR-	Metastatic 1L	BEGONIA durvalumab combination Ph1b/2 (Arm 6)	
		Neoadjuvant		

*Adjuvant therapy for patients with HER2+ early BC with high risk of disease recurrence who have residual invasive disease after receiving neoadjuvant therapy

Ph 1 ongoing Ph 2 ongoing Ph 3 ongoing New Completed

Study initiation & end points are all shown as either beginning of H1 or H2

AC: adriamycin + cyclophosphamide, HR: hormone receptor, PC: physician's choice, T-DM1: trastuzumab emtansine, T-DXd: trastuzumab deruxtecan, THP: taxane + Herceptin + pertuzumab,

ENHERTU®: Clinical Development Plan | GC & NSCLC

As of Dec 2022		FY2022	FY2023	FY2024	
Gastric	HER2 Positive	Metastatic 3L+	DESTINY-Gastric06 monotherapy China Ph2		
			DESTINY-Gastric02 West		
		Metastatic 2L	DESTINY-Gastric04 mono vs ramucirumab+paclitaxel		
		Metastatic 1L	DESTINY-Gastric03 combination (2L/1L) Ph1b/2		
NSCLC	HER2 Expressing	Metastatic 2L+	DESTINY-Lung01 completed		
			HUDSON durvalumab combination		
		Metastatic 2L			
	Metastatic 1L	DESTINY-Lung03 combination			
	HER2 Mutant	Metastatic 2L+	DESTINY-Lung01 completed		
			DESTINY-Lung02 monotherapy		
		DESTINY-Lung05 China			
	Metastatic 1L	DESTINY-Lung04 mono vs SOC			

Ph 1 ongoing
Ph 2 ongoing
Ph 3 ongoing
New
Completed

Study initiation & end points are all shown as either beginning of H1 or H2

NSCLC: non-small cell lung cancer, SOC: standard of care

ENHERTU[®]: Clinical Development Plan | CRC & other tumors

As of Dec 2022			FY2022	FY2023	FY2024
CRC	HER2 Expressing	Metastatic 3L	DESTINY-CRC02 monotherapy		
Other Tumors/ multiple tumors	HER2 Expressing	Metastatic 2L	Pembrolizumab combination (breast, NSCLC)		
			DESTINY-PanTumor02		
	HER2 Mutant	Metastatic 2L	DESTINY-PanTumor01		
			PETRA AZD5305 combination Ph1/2a (Module 4)		

Ph 1 ongoing
Ph 2 ongoing
Ph 3 ongoing
New
Completed

Study initiation & end points are all shown as either beginning of H1 or H2

CRC: colorectal cancer, NSCLC: non small cell lung cancer

Dato-DXd: Clinical Development Plan | NSCLC

As of Dec 2022		FY2022	FY2023	FY2024
NSCLC	All comers	Metastatic 2L/3L	TROPION-Lung01 monotherapy	
	ICI combination Without actionable genomic alterations	Metastatic 1L/2L	TROPION-Lung02 pembrolizumab combination	
			TROPION-Lung04 durvalumab combination	
		Metastatic 1L	TROPION-Lung07 pembrolizumab ± pemetrexed combination (PD-L1 < 50%) Ph3	
	With actionable genomic alterations	Metastatic 2L+	TROPION-Lung05 monotherapy	
Metastatic 2L with EGFR mutation			ORCHARD osimertinib combination (Module10)	



Study initiation & end points are all shown as either beginning of H1 or H2

ICI: immune checkpoint inhibitor, NSCLC: non small cell lung cancer

Dato-DXd: Clinical Development Plan | Breast & other tumors

As of Dec 2022			FY2022	FY2023	FY2024
Breast	HR+/HER2-	Metastatic 3L+	TROPION-Breast01		
		Metastatic 2L+	TROPION-PanTumor01		
	TNBC	Metastatic 1L	TROPION-Breast02		
		Adjuvant**	TROPION-Breast03 (Ph3)		
Other Tumors*			TROPION-PanTumor01		
			PETRA AZD5305 combination Ph1/2a (Module 5)		
			TROPION-PanTumor03 (Ph2)		

*Other tumors are gastric, esophageal, urothelial, SCLC, endometrial, CRPC, etc. Inclusion of these tumors is based upon TROP2 expression as well as preclinical and other evidence that Dato-DXd may be effective.

**Adjuvant therapy for patients with TNBC with residual disease after neoadjuvant therapy

Ph 1 ongoing Ph 2 ongoing Ph 3 ongoing New Completed

Study initiation & end points are all shown as either beginning of H1 or H2

CRPC: Castration-resistant prostate cancer, HR: hormone receptor, SCLC: small cell lung cancer, TNBC: triple-negative breast cancer

HER3-DXd: Clinical Development Plan | NSCLC & other tumors

As of Dec 2022			FY2022	FY2023	FY2024
NSCLC	EGFR mutated	Advanced/ Metastatic 3L~	Ph1 dose expansion		
			HERTHENA-Lung01 monotherapy		
		Advanced/ Metastatic 2L	HERTHENA-Lung02 monotherapy vs chemotherapy		
		Advanced/ Metastatic 1L	Osimertinib combination Ph1b		
Breast		Metastatic BC	Monotherapy Ph1/2		



Study initiation & end points are all shown as either beginning of H1 or H2

BC: breast cancer, NSCLC: non small cell lung cancer

Contact address regarding this material

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

TEL: +81-3-6225-1125

Email: DaiichiSankyoIR@daiichisankyo.co.jp